Literature DB >> 32039288

The enduring promise of phosphodiesterase 5 inhibitors for colon cancer prevention.

Darren D Browning1.   

Abstract

Entities:  

Year:  2019        PMID： 32039288      PMCID： PMC6987326          DOI： 10.21037/tgh.2019.12.10

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  25 in total

1.  Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis.

Authors:  Shengbing Zhao; Shuling Wang; Peng Pan; Tian Xia; Xin Chang; Xia Yang; Liliangzi Guo; Qianqian Meng; Fan Yang; Wei Qian; Zhichao Xu; Yuanqiong Wang; Zhijie Wang; Lun Gu; Rundong Wang; Fangzhou Jia; Jun Yao; Zhaoshen Li; Yu Bai
Journal:  Gastroenterology       Date:  2019-02-06       Impact factor: 22.682

2.  Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.

Authors:  Wuqing Huang; Jan Sundquist; Kristina Sundquist; Jianguang Ji
Journal:  Gastroenterology       Date:  2019-05-16       Impact factor: 22.682

3.  Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.

Authors:  Wen-Qing Li; Abrar A Qureshi; Kathleen C Robinson; Jiali Han
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

4.  Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.

Authors:  Bianca N Islam; Sarah K Sharman; Yali Hou; Allison E Bridges; Nagendra Singh; Sangmi Kim; Ravindra Kolhe; Jimena Trillo-Tinoco; Paulo C Rodriguez; Franklin G Berger; Subbaramiah Sridhar; Darren D Browning
Journal:  Cancer Prev Res (Phila)       Date:  2017-05-03

5.  Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.

Authors:  K Shailubhai; H H Yu; K Karunanandaa; J Y Wang; S L Eber; Y Wang; N S Joo; H D Kim; B W Miedema; S Z Abbas; S S Boddupalli; M G Currie; L R Forte
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

6.  The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.

Authors:  Jieru Egeria Lin; Peng Li; Adam Eugene Snook; Stephanie Schulz; Abhijit Dasgupta; Terry Marie Hyslop; Ahmara Vivian Gibbons; Glen Marszlowicz; Giovanni Mario Pitari; Scott Arthur Waldman
Journal:  Gastroenterology       Date:  2009-09-06       Impact factor: 22.682

7.  Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.

Authors:  Eric D Shah; Hyungjin Myra Kim; Philip Schoenfeld
Journal:  Am J Gastroenterol       Date:  2018-01-30       Impact factor: 10.864

8.  Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.

Authors:  Peng Li; Stephanie Schulz; Alessandro Bombonati; Juan P Palazzo; Terry M Hyslop; Yihuan Xu; Amy A Baran; Linda D Siracusa; Giovanni M Pitari; Scott A Waldman
Journal:  Gastroenterology       Date:  2007-06-02       Impact factor: 22.682

9.  Effects of Family History on Relative and Absolute Risks for Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Victorine H Roos; Carolina Mangas-Sanjuan; Mar Rodriguez-Girondo; Lucia Medina-Prado; Ewout W Steyerberg; Patrick M M Bossuyt; Evelien Dekker; Rodrigo Jover; Monique E van Leerdam
Journal:  Clin Gastroenterol Hepatol       Date:  2019-09-13       Impact factor: 11.382

10.  Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials.

Authors:  Sajesh K Veettil; Nattawat Teerawattanapong; Siew Mooi Ching; Kean Ghee Lim; Surasak Saokaew; Pochamana Phisalprapa; Nathorn Chaiyakunapruk
Journal:  Onco Targets Ther       Date:  2017-05-23       Impact factor: 4.147
View more
  3 in total

1.  Inhibition of Colon Cancer Cell Growth by Phosphodiesterase Inhibitors Is Independent of cGMP Signaling.

Authors:  Yali Hou; Alexis Wren; Namratha Mylarapu; Kaylin Browning; Bianca N Islam; Rui Wang; Kenneth J Vega; Darren D Browning
Journal:  J Pharmacol Exp Ther       Date:  2022-02-02       Impact factor: 4.030

Review 2.  How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.

Authors:  Mehdi Sanati; Samaneh Aminyavari; Hamid Mollazadeh; Bahram Bibak; Elmira Mohtashami; Amir R Afshari
Journal:  Pharmacol Rep       Date:  2022-01-20       Impact factor: 3.024

Review 3.  Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.

Authors:  Patrizia Di Iorio; Maurizio Ronci; Patricia Giuliani; Francesco Caciagli; Renata Ciccarelli; Vanni Caruso; Sarah Beggiato; Mariachiara Zuccarini
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.